Clinical Trial Update: A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical study evaluating SHR-A1811 in combination with chemotherapy for platinum-sensitive recurrent ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: RECRUITING